Compare Charles River Laboratories Intl. Inc (CRL) vs NICE Ltd (NICE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs NICE Ltd — how do they compare? Charles River Laboratories Intl. Inc trades at $227.51 (market cap $11.14B), while NICE Ltd trades at $101.25 (market cap $6.00B). The key difference: Charles River Laboratories Intl. Inc is the larger of the two by market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, NICE Ltd nearer its low. Which is the better fit depends on your goals.
| CRL | NICE | |
|---|---|---|
Market Cap | $11.14B | $6.00B |
Sector | Health | Technology |
52-Week High | $233.60 | $170.37 |
52-Week Low | $145.57 | $83.15 |
Enterprise Value | $14.00B | $5.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
NICE stock trades at $103.48, up 3.75% today, with strong technical momentum and bullish analyst sentiment. The company demonstrates robust fundamentals with a 65.79% gross margin and consistent earnings beats, including Q1 2026 EPS of $2.64 beating expectations of $2.52. Recent news highlights enterprise AI deployments with Banco do Brasil and Sopra Steria, expanding NICE's global footprint in customer experience solutions.
NICE presents a compelling investment case with attractive valuation (P/E 12.13) and 56.5% analyst buy ratings targeting $124.88 consensus. Key risks include execution challenges in AI integration and competitive pressure from larger tech players. The stock's current proximity to 52-week highs requires monitoring for sustainability of recent gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
